ArticlePloS one2010
Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04642482 (The Effect of Synbiotic on Intestinal Microbiota and HOMA-IR), which is not on this map. Cited by 1,452 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Synbiotic on Intestinal Microbiota and HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) on Obesity
Who cites it
1,452 citing papers in PubMed, 6 syntheses or guidelines pooled it, 2,953 citations in OpenAlex.
- Berberine-gut microbiota interactions based on CiteSpace: current research status and hotspots.Frontiers in microbiology · 2026Pooled it
- Frontiers and emerging trends in research on metabolic syndrome and metabolic dysfunction-associated fatty liver disease: a bibliometric analysis (2005-2024).Frontiers in endocrinology · 2026Pooled it
- Pooled it
- Gut microbiota and type 2 diabetes associations: a meta-analysis of 16S studies and their methodological challenges.Frontiers in microbiomes · 2025Pooled it
- The impact of bariatric surgery on gut microbiota: a bibliometric analysis of research trends and scientific contributions.Frontiers in microbiology · 2025Pooled it
- Short-chain fatty acids and type 2 diabetes: a bibliometric analysis of knowledge structure, research hotspots, and future directions.Frontiers in microbiology · 2025Pooled it
- Trial
- Childhood obesity and insulin resistance is correlated with gut microbiome serum protein: an integrated metagenomic and proteomic analysis.Scientific reports · 2025Trial
- The Efficacy of Cheonggukjang in Alleviating Menopausal Syndrome and Its Effects on the Gut Microbiome: A Randomized, Double-Blind Trial.Nutrients · 2025Trial
- Acute myeloid leukemia and gut microbiome: bidirectional effects and opportunities for intervention.Annals of hematology · 2026Review
- Effect of Probiotics on the Gut-Mammary Pathway: Implications on Infant Microbiota Transfer and Development.Current nutrition reports · 2026Review
- From Inclusion Complexes to Metabolic Signaling: The Emerging Role of γ-Cyclodextrin in Gut Microbiota and Metabolic Regulation.Molecules (Basel, Switzerland) · 2026Review
- Mediterranean Dietary Pattern in Type 2 Diabetes Management: Pathways and Clinical Evidence.Biomedicines · 2026Review
- The eternal struggle between titans: Fecal microbiota transplant (FMT) versus metformin in type 2 diabetes (T2D) gut dysmotility.Journal of advanced research · 2026Review
- Early diabetes-like phenotypes in germ-free mice induced by gut microbiota from patients with type 2 diabetes.Animal models and experimental medicine · 2026Article
- Metformin in Diabetes and Beyond: Therapeutic Mechanisms, Lactic Acidosis, Organ-Specific Effects, and Nanotechnology-Based Delivery Strategies.Current medical science · 2026Review
- Exploring the Multifunctional Benefits of Astaxanthin in Aging, Oxidative Stress, Immune Dysfunction, Gut and Skin Health.Antioxidants (Basel, Switzerland) · 2026Review
- Elucidating the Probiotic Potential of Lactobacillus and Bifidobacterium Species in Modulating Glucose Metabolism and Inflammation in Gestational Diabetes Mellitus: A Scoping Review.Nutrition reviews · 2026Article
- Review
- Article
1,392 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent evidence suggests that there is a link between metabolic diseases and bacterial populations in the gut. The aim of this study was to assess the differences between the composition of the intestinal microbiota in humans with type 2 diabetes and non-diabetic persons as control. METHODS AND
findingsThe study included 36 male adults with a broad range of age and body-mass indices (BMIs), among which 18 subjects were diagnosed with diabetes type 2. The fecal bacterial composition was investigated by real-time quantitative PCR (qPCR) and in a subgroup of subjects (N = 20) by tag-encoded amplicon pyrosequencing of the V4 region of the 16S rRNA gene. The proportions of phylum Firmicutes and class Clostridia were significantly reduced in the diabetic group compared to the control group (P = 0.03). Furthermore, the ratios of Bacteroidetes to Firmicutes as well as the ratios of Bacteroides-Prevotella group to C. coccoides-E. rectale group correlated positively and significantly with plasma glucose concentration (P = 0.04) but not with BMIs. Similarly, class Betaproteobacteria was highly enriched in diabetic compared to non-diabetic persons (P = 0.02) and positively correlated with plasma glucose (P = 0.04).
conclusionsThe results of this study indicate that type 2 diabetes in humans is associated with compositional changes in intestinal microbiota. The level of glucose tolerance should be considered when linking microbiota with metabolic diseases such as obesity and developing strategies to control metabolic diseases by modifying the gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.